Collectively, these findings revealed that mechanistically LAPTM5 acts as a regulator of NASH progression and clinically it might also serve as an indicator for NASH progression and a target for the treatment of NASH. The gene discussed is LAPTM5; the disease is metabolic dysfunction-associated steatohepatitis.